Form 4: Pulmonx Director Richard Ferrari Receives RSU Grant

Director Richard Ferrari was granted 40,000 restricted stock units in Pulmonx Corporation.

Summary

• Director Richard Ferrari acquired 40,000 restricted stock units (RSUs) of Pulmonx Corporation common stock.
• The transaction occurred on June 5, 2026.
• The RSUs were granted at a price of $0 per share.
• Following this transaction, the reporting person's total beneficial ownership is 127,024 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no immediate impact on company operations or financial health.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the vesting and issuance of the underlying common stock.

Risks

• Market volatility affecting the value of equity compensation.

Future Outlook

The RSUs vest on the earlier of the one-year anniversary of the grant date (June 5, 2027) or the date of the next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practice to ensure long-term alignment between leadership and shareholder interests in the medical device sector.

Comparison to Industry Standards

• The grant of RSUs to non-employee directors is consistent with standard compensation practices for publicly traded medical technology companies.

Stakeholder Impact

• Minor dilution impact for existing shareholders upon future vesting.

Next Steps

• Vesting of the 40,000 RSUs on June 5, 2027, or the date of the next annual meeting.

Key Dates

Keywords

Pulmonx, LUNG, Form 4, Insider Trading, Director Compensation, Restricted Stock Units